Cookies on this site

Researchers from the Kennedy Institute of Rheumatology will join international partners in a bid to transform how chronic inflammatory disease is treated.

Person with inflammation on their elbow

Chronic inflammatory diseases, such as arthritis, inflammatory bowel disease, autoimmune liver disease and Sjögren’s disease, currently require lifelong management but, with further investment in research investigating the cause of these diseases, it is possible that curative treatments could be found.

Kennedy Institute researchers will join a team of leading scientists, doctors and patient research partners as part of the new £50m UKRI Medical Research Council (MRC) Centre of Research Excellence (CoRE) for Restorative Immunology, funded over the next 14 years and led by a team of investigators from across the UK and Japan.

The MRC CoRE aims to transform the lives of people facing debilitating immune-mediated diseases which, as well as being a major burden on affected individuals, have considerable impact on health services and the wider economy.

These conditions arise when the body’s immune system mistakenly attacks healthy tissues, including the joints, gut, skin, eyes, liver and salivary glands, among many others. The resulting inflammation can cause irreversible tissue and organ damage, chronic pain and lifelong disability.

Despite major advances in treatment, many people, including those whose disease begins in childhood, require lifelong therapy to control inflammation and prevent further damage. The impact can be profound, affecting health, independence and quality of life.

The research will bring together experts from eight universities, charities, public engagement organisations, industry and biotechnology, combining different skills and perspectives to improve the lives of patients and train the next generation of researchers.

The University of Oxford is a key partner in the MRC Centre of Excellence for Restorative Immunology, bringing expertise in translational immunology, inflammation research, and advanced human tissue analysis. Researchers at the Kennedy Institute of Rheumatology will contribute to understanding how immune and tissue-resident stromal cells interact to drive chronic inflammatory disease, and how these pathways can be harnessed to promote tissue repair and restore healthy immune function. Oxford's interdisciplinary strengths in basic discovery science, clinical research and experimental medicine will help accelerate the translation of fundamental insights into new approaches for patients with immune-mediated diseases.

Chris Buckley, Kennedy Professor of Translational Rheumatology and Director of Clinical Research said: ‘This partnership creates an exciting framework for bringing together researchers, clinicians industry partners and patients to tackle some of the most challenging immune-mediated diseases. Our goal is not only to understand how to reset disease mechanisms within tissues but ultimately to translate those discoveries into treatments that restore health and improve patients' lives.’

Professor Adam P Croft, Arthritis UK Chair of Rheumatology and Director of the MRC CoRE in Restorative Immunology explains: ‘While remarkable advances have been made in the treatment of immune-mediated inflammatory diseases over the past two decades, the focus has largely been on controlling inflammation to relieve symptoms and prevent damage to tissues.

New technologies now allow us to study diseased tissues at unprecedented resolution, revealing how healthy tissue becomes diseased and identifying the cells and molecular pathways that drive this process. Combined with the development of therapies capable of precisely targeting these cells and pathways, this creates a realistic opportunity to move beyond lifelong disease control towards treatments delivered with curative intent – with the ultimate goal of restoring long-term health and wellbeing.’

Dr Ceri Williams, Executive Director of Challenge Led Portfolio at MRC, said: ‘MRC Centres of Research Excellence are designed to tackle some of the most important challenges in biomedical research through sustained, ambitious and collaborative science. By doing so, they contribute to UKRI’s mission to advance knowledge, improve lives and drive growth across the UK.

‘The MRC CoRE for Restorative Immunology exemplifies that vision. Moving beyond treating symptoms to achieve lasting remission or cure will require a deeper understanding of how healthy tissues become disrupted and how those processes can be reversed.

‘By bringing together expertise from across disciplines, sectors and countries to tackle these fundamental questions, this centre has the potential to transform our understanding of inflammatory disease and accelerate the development of treatments that deliver lasting benefits for patients.’

Similar stories

Arthritis origins may begin before birth, study finds

Researchers at the Kennedy Institute have discovered that some joints may be more susceptible to inflammatory arthritis before birth, offering new insight into why rheumatoid arthritis attacks particular joints while sparing others.

Oxford researchers awarded ARIA funding to develop transformative anti-viral therapies

Three innovative research projects aimed at transforming how we protect against respiratory viruses, led by teams at the University of Oxford, have secured funding through the UK’s Advanced Research and Invention Agency (ARIA).

Natural compound may help boost vaccine responses in older adults

Researchers from the Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences (NDORMS) have found that a naturally occurring compound called spermidine may help improve vaccine responses in some older adults by reducing signs of immune system ageing.

Researchers uncover hidden mechanism behind a major cancer therapy target

Kennedy researchers have revealed how one of the immune system's most important regulatory pathways operates at the earliest moments of T cell activation, providing new insights that could help improve cancer immunotherapy.

Major MRC funding for Irina Udalova to unravel neutrophil behaviour across immune pathologies

Prof Irina Udalova has received a programme grant of £2.7M from the Medical Research Council (MRC) to investigate how neutrophils – a type of white blood cell that forms the body’s first line of defence – adapt their behaviour to tissue requirements and contribute to immune diseases, leading to the development of a new class of neutrophil-targeted therapeutics.

Researchers find clue to how Sjögren’s disease persists

A new study has found that a protein TRIM21 linked to Sjögren’s disease may be fuelling the condition in an unexpected way. Researchers at the Kennedy Institute of Rheumatology have discovered that during a specific type of cell death, TRIM21 is released and combines with antibodies to overstimulate the immune system, potentially maintaining the symptoms of Sjögren’s disease.

Similar stories

Arthritis origins may begin before birth, study finds

Researchers at the Kennedy Institute have discovered that some joints may be more susceptible to inflammatory arthritis before birth, offering new insight into why rheumatoid arthritis attacks particular joints while sparing others.

Oxford researchers awarded ARIA funding to develop transformative anti-viral therapies

Three innovative research projects aimed at transforming how we protect against respiratory viruses, led by teams at the University of Oxford, have secured funding through the UK’s Advanced Research and Invention Agency (ARIA).

Natural compound may help boost vaccine responses in older adults

Researchers from the Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences (NDORMS) have found that a naturally occurring compound called spermidine may help improve vaccine responses in some older adults by reducing signs of immune system ageing.

Researchers uncover hidden mechanism behind a major cancer therapy target

Kennedy researchers have revealed how one of the immune system's most important regulatory pathways operates at the earliest moments of T cell activation, providing new insights that could help improve cancer immunotherapy.

Major MRC funding for Irina Udalova to unravel neutrophil behaviour across immune pathologies

Prof Irina Udalova has received a programme grant of £2.7M from the Medical Research Council (MRC) to investigate how neutrophils – a type of white blood cell that forms the body’s first line of defence – adapt their behaviour to tissue requirements and contribute to immune diseases, leading to the development of a new class of neutrophil-targeted therapeutics.

Researchers find clue to how Sjögren’s disease persists

A new study has found that a protein TRIM21 linked to Sjögren’s disease may be fuelling the condition in an unexpected way. Researchers at the Kennedy Institute of Rheumatology have discovered that during a specific type of cell death, TRIM21 is released and combines with antibodies to overstimulate the immune system, potentially maintaining the symptoms of Sjögren’s disease.